




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/505, 31/415	A1	(11) International Publication Number: WO 00/00200 (43) International Publication Date: 6 January 2000 (06.01.00)
---	----	---

(21) International Application Number: PCT/SE99/01144 (22) International Filing Date: 23 June 1999 (23.06.99) (30) Priority Data: 9802333-6 29 June 1998 (29.06.98) SE (71) Applicant (for all designated States except MG US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts. WD4 8DH (GB). (71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): HAMLEY, Peter [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). TINKER, Alan [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
--	--

(54) Title: A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR



(57) Abstract

The invention relates to the co-administration of an inhibitor of induced nitric oxide synthase of formula (I) and an inhibitor of cyclooxygenase-2 for the treatment of inflammation and inflammatory disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR

The present invention relates to the co-administration of an inhibitor of induced nitric oxide synthase and an inhibitor of cyclooxygenase-2 for the treatment of inflammation and inflammatory disorders, such as arthritis, inflammatory bowel disease and CNS inflammatory disorders.

The excessive production of nitric oxide (NO) has been implicated in immune and inflammatory responses and as an important and novel mechanism in the pathology of a variety of chronic inflammatory diseases (Moncada S. et al, *Pharmacol. Rev.*, 1991, 43, 109). The role of NO, as either a beneficial physiological mediator, or as pathological cytotoxic radical, is largely determined by the level and extent of synthesis. Under physiological conditions only low levels of NO are required for effector functions, whereas excessive NO production may be detrimental and pathological.

15 The synthesis of NO from the semi-essential amino acid L-arginine is catalysed by three different enzyme isoforms: endothelial NOS (eNOS) and neuronal NOS (nNOS) are constitutively expressed, calcium dependent enzymes and play a major role in normal physiology. The third major NOS isoform, inducible NOS (iNOS) is not expressed under 20 physiological conditions but requires induction. Inflammatory stimuli, such as endotoxin and the cytokines interleukin-1 (IL-1), tumour necrosis factor- α (TNF α) or interferon gamma (INF γ), induce *de novo* formation of a calcium independent NOS in a variety of cells, including epithelial cells, macrophages and neutrophils. The inducible NOS (iNOS) produces much greater amounts of NO for longer periods compared to the constitutive 25 enzymes.

There is considerable evidence for an important role for iNOS in inflammation. The excessive NO production following induction of NO synthase plays an important role in the vascular permeability in intestinal inflammation produced by endotoxin. Inhibitors of iNOS 30 attenuate the increase in plasma leakage (Boughton-Smith N. K. et al, *Eur. J. Pharmacol.*,

1990, **191**, 485). Inhibitors of iNOS reduce plasma leakage produced in zymosan peritonitis and by carrageenan in the rat paw and air pouch, in which there are increases in iNOS activity (Ialenti A., *Eur. J. Pharmacol.*, 1992, **211**, 177; Salvemini D. et al, *J. Clin. Invest.*, 1995, **96**, 301; Salvemini D. et al, *Br. J. Pharmacol.*, 1996, **118**, 829; Boughton-Smith N.K. and Ghelani A., *Inflamm. Res.*, 1995, Suppl. 2, S149). In rat adjuvant arthritis there are increases in plasma nitrite and NO production by peritoneal macrophages and immunoreactive iNOS is localised to synovial tissue. Paw swelling, loss in weight gain, synovial inflammation and cartilage degradation are reduced by the non-selective NOS inhibitors L-NAME and L-NMMA (Ialenti A. et al, *Br. J. Pharmacol.*, 1993, **110**, 701; Stefanovic-Racic M., *Arthritis and Rheumatism*, 1994, **37**, 1062; Stefanovic-Racic M. et al, *Rheumatol.*, 1995, **22**, 1922). Inhibitors of NOS also have beneficial effects in a rat model of arthritis induced by streptococcal cell wall (McCartney-Frances N., *J. Exp. Med.*, 1993, **178**, 749) and in the spontaneous arthritis and nephritis produced in MLR lpr/lpr mice, in which there is also evidence of iNOS induction (Weinberg J.B., *J. Exp. Med.*, 1994, **179**, 651). There are also increases in NOS activity in animal models of inflammatory bowel disease and an inhibitor of NOS ameliorates guinea-pig model ileitis (Boughton-Smith N.K. et al, *Agents and Actions*, 1994, **41**, 223; Miller M.J.S., *J. Pharmacol. Exp. Ther.*, 1993, **264**, 11).

20 In clinical studies there are increases in the production of NO and in iNOS expression in a variety of chronic inflammatory diseases, such as rheumatoid and osteoarthritis (Farrell A.J. et al, *Ann Rheum. Dis.*, 1992, **51**, 1219; Grabowski P.S. et al, *Arth. & Rheum.*, 1996, **39**, 643; Stichtenoth D.O. et al, *Ann of the Rheumatic Diseases*, 1995, **54**, 820; McInnes I.B. et al, *J. Exp. Med.*, 1996, **184**, 1519), inflammatory bowel disease (Boughton-Smith N.K. et al, *Lancet*, 1993, **342**, 338; Lundberg J.O.N. et al, *Lancet*, 1994, **344**, 1673; Middleton S.J. et al, *Lancet*, 1993, **341**, 465), psoriasis (Rowe A. et al, *Lancet*, 1994, **344**, 1371; Bruch-Gerharz D. et al, *J. Exp. Med.*, 1996, **184**, 2007) and asthma (Hamid Q. et al, *Lancet*, 1993, **342**, 1510; Barnes J. and Liew F.Y., *Immunol. Today*, 1995, **16**, 128) and iNOS is implicated as a major pathological factor in these chronic inflammatory diseases. Thus, there is considerable evidence that inhibition of excessive NO production by iNOS will be anti-inflammatory. Since the production of NO from eNOS and nNOS is involved in normal

physiology, it is important that any NOS inhibitor used therapeutically for treating inflammation is selective for iNOS. Such an inhibitor will inhibit the excessive production of NO by iNOS without effecting the modulation of blood pressure produced by NO production from eNOS or the non-adrenergic non-cholinergic neuronal transmission produced by NO from nNOS.

The recent discovery of an inducible isoform of cyclooxygenase (COX-2) has provided a specific target for inhibition of inflammatory prostaglandin synthesis while leaving the physiological actions of prostaglandins formed by constitutive cyclooxygenase (COX-1) intact (Fu et al, *J. Biol. Chem.*, 1989, **265**, 16740; DeWitt D., *Biophys. Acta*, 1991, **1083**, 121; Masferrer J.L. and Seibert, *Receptor*, 1994, **94**, 17). Prostaglandins play an important role in inflammation, for example in both the pain and swelling associated with arthritis. The commonly used cyclooxygenase inhibitors or non-steroid anti-inflammatory drugs (NSAIDs) are non-selective in that they reduce prostaglandins involved in inflammatory pain and swelling but also inhibit the physiological prostaglandin formation which is required particularly for maintenance of gastrointestinal integrity. A number of selective COX-2 inhibitors have been described which are anti-inflammatory in a variety of animal models but which, unlike non-selective COX inhibitors, do not produce gastrointestinal pathology.

Since both iNOS and COX-2 inhibitors are selective for the enzyme isoforms induced in inflammation which produce NO and prostaglandins respectively, and will not effect the constitutive enzymes involved in normal physiology, the combination will have a substantially reduced level of adverse side effects associated with NSAIDs and also anti-inflammatory glucocorticoids, which inhibit the induction of both enzymes (Radomski M.V. et al, *Proc. Natl. Acad. Sci. USA*, 1990, **87**, 10043; Masferrer J.L. et al, *J. Clin. Invest.*, 1990, **86**, 1375).


Compounds that selectively inhibit COX-2 have been described in US patents 5,380,738; 5,344,991; 5,466,823; 5,434,178; 5,474,995; 5,510,368; 5,521,207 and 5,604,260.

Compounds that selectively inhibit iNOS have been described in US patents 5,132,453 and 5,273,875.

Combination therapies of NSAIDs with other drugs targeted at different mechanisms are known in the art. A combination of the analgesic diflunisal and an antispasmodic compound has been described (Basmajian J., *Spine*, 1989, 14, 438). Also, a combination of ibuprofen with an antispasmodic to reduce morning stiffness in primary fibromyalgia syndrome (Fossaluzza V. and DeVita S., *Int. J. Clin. Pharm. Res.*, 1992, 12, 99) and a combination of tetracycline with flurbiprofen for the treatment of rheumatoid arthritis (Greenwald R. et al, *J. Rheumatol.*, 1992, 19, 927) are known.

However, COX-2 inhibitors (and other NSAIDs) do not have complete efficacy and do not completely overcome the inflammatory condition being treated, even at optimal doses. There is therefore a need to improve the efficacy of COX-2 inhibitors. It has now been found that the efficacy of a COX-2 inhibitor can be improved if it is combined with a iNOS inhibitor, and as a result inflammatory diseases may be treated with a combination of an iNOS inhibitor and a COX-2 inhibitor. Although it has been said that some of the inflammatory actions of iNOS are dependent on the secondary activation of COX and an increase in prostaglandin formation (Salvemini D. et al, *Proc. Nat. Acad. Sci. USA*, 1993, 90, 7240; Salvemini et al, *J. Clin. Invest.*, 1995, 96, 301) it is believed that a combination of selective inhibitors of iNOS and COX-2 will lead to a substantially greater anti-inflammatory efficacy compared with the efficacy of each agent alone. By inhibiting iNOS and COX-2 at inflammatory sites the combination will result in a greater and more complete reduction in the severity of inflammation in a variety of inflammatory diseases and inflammation related disorders.

In a first aspect the invention provides a pharmaceutical combination comprising a COX-2 inhibitor and a compound of formula (I):



wherein:-

R¹ and R¹⁹ independently represent hydrogen, alkyl C1 to 6, alkoxy C1 to 6, alkylthio C1 to 6, halogen, hydroxyl or amino;

(i) R³ represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1 to 6, alkoxy C1 to 6, halogen, hydroxyl, alkylthio C1 to 6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group —(CH₂)_c·NHCO₂R¹⁰, a group —(CH₂)_c·NR⁵R⁶, or a group —CO₂R¹¹, and R⁴ represents hydrogen or alkyl C1 to 6; or

(ii) R³ represents hydrogen or alkyl C1 to 8, which alkyl group may be optionally substituted by amino or a group —NHCO₂R¹⁰, and R⁴ represents hydrogen or alkyl C1 to 6; or

(iii) R³ and R⁴ taken together represent a group (CH₂)_a·Z·(CH₂)_b;

c represents zero, 1 or 2;

a and b independently represent an integer 1 to 3;

Z represents CH₂, NH, a group >N(CH₂)_nYR¹³, a group >NCOX(CH₂)_nYR¹³, a group >NCSX(CH₂)_nYR¹³, or a group >NCNMX(CH₂)_nYR¹³;

X represents O, S or a bond;

Y represents O, S, SO, SO₂, NR⁹ or a bond;

n represents zero or an integer from 1 to 6;

(a) R^{13} represents alkyl C1 to 6, cyano, quinolyl, phenyl, naphthyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, a benzene ring fused with a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S or alkyl C1 to 6 substituted by one or more halogen atoms; or

(b) R^{13} may be as defined in (a) except that when it contains one or more aromatic rings, said rings may be optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl, trifluoromethoxy, methanesulphonyl, sulphamoyl, $-NR^{14}R^{15}$, $-COOR^{16}$ or $-CONR^7R^8$; or

(c) R^{13} may represent a phenyl ring, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S substituted by: benzyloxy or optionally substituted phenyl or an optionally substituted 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S; wherein the optional substituents are alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl and trifluoromethoxy; or

(d) R^{13} may be as defined in (a), (b) or (c) except that when it contains a heterocyclic aromatic ring containing at least one nitrogen atom, said ring may be optionally substituted by one or more oxo groups adjacent to the nitrogen, the ring being attached to the remainder of the molecule through one of the nitrogen atoms or otherwise;

$R^2, R^5, R^6, R^{11}, R^9, R^{14}, R^{15}$ and R^{16} independently represent hydrogen or alkyl C1 to 6; in addition, when Y represents NR^9 , $-NR^9R^{13}$ may together represent a pyrrolidine or piperidine ring;

R^{10} represents alkyl C1 to 6; and

R^7 and R^8 independently represent hydrogen, alkyl C1 to 6 or phenyl optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl and trifluoromethoxy;

or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.

Such a combination has been found to have pharmaceutical activity, especially for treating inflammatory disease.

5

Another aspect of the invention provides the use of the combination described above, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.

10 The invention also provides a method of treatment or prophylaxis of an inflammatory disease in a person suffering from or susceptible to such a disease, which method comprises administering to the person a therapeutically effective amount of the combination.

15 Preferred iNOS inhibitors for use in the combinations of the invention include compounds known from WO 97/14686. In particular, the compound of formula (I) for use in the present invention can be any of the iNOS inhibitors of Examples 1 to 257 disclosed in WO 97/14686, or any other pharmaceutically acceptable salt, enantiomer or tautomer thereof.

20 Preferably R³ and R⁴ taken together represent a group (CH₂)_a·Z·(CH₂)_b, in which Z represents a group >NCO(CH₂)_nR¹³, a group >NCS(CH₂)_nR¹³, or a group >NCNH(CH₂)_nR¹³ and R¹³ represents optionally substituted phenyl, furyl, thienyl, thiazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyridyl or pyrazinyl. In such a case, it is further preferred that n represents zero, and R¹³ represents substituted phenyl or substituted pyridyl, wherein the substituent is in the *para* position.

25 Preferably R¹ and R¹⁹ independently represent hydrogen or halogen, more preferably at least one of R¹ and R¹⁹ represents fluoro or chloro. R¹ may especially represent 5-fluoro or 5-chloro, and in particular R¹ may represent 5-fluoro and R¹⁹ 8-fluoro.


When R³ and R⁴ taken together represent a group (CH₂)_a·Z·(CH₂)_b, it is preferred that a and b each represent 2.

Preferably R² represents hydrogen.

When R⁴ represents hydrogen, it is preferred that R³ represents ethyl, isopropyl, cyclopropyl or cyclobutyl; or furyl, thienyl or substituted phenyl wherein the substituent is fluoro or hydroxyl.

5 Alternatively, when R³ and R⁴ taken together represent a group (CH₂)_aZ(CH₂)_b, in which Z represents a group >NCO₂(CH₂)_nYR¹³ or >NCSO(CH₂)_nYR¹³, it is preferred that n represents 0, Y represents a bond and R¹³ represents alkyl C1 to 6 or chloroalkyl C3 to 6; or n may represent 2, Y represent oxygen and R¹³ represent optionally substituted phenyl or pyridyl.

10 In one particular aspect of the invention, the preferred iNOS inhibitor is a compound of formula (IA)



wherein

R¹ represents hydrogen, alkyl C1 to 6, alkoxy C1 to 6 or halogen;

a and b independently represent an integer 1 to 3;

15 X represents O, S or a bond;


Y represents O, S, NR⁹ or a bond;

n represents an integer 0 to 4;

20 R¹³ represents alkyl C1 to 6, cyano, trifluoromethyl, phthalimido, quinolyl, phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S or a benzene ring fused with a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S;

or R¹³ may be as defined above except that when it contains one or more aromatic rings, said rings may be optionally substituted by one or more groups selected from alkyl C1 to 6,

halogen, cyano, nitro, hydroxy, alkoxy C1 to 6, trifluoromethyl, trifluoromethoxy, sulphonylmethyl, sulphonylamino, —NR¹⁴R¹⁵, —COOR¹⁶ or —CONR⁷R⁸;
 or R¹³ may represent a phenyl ring substituted by benzyloxy or optionally substituted phenyl or an optionally substituted 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, wherein the optional substituents are alkyl C1 to 6, halogen, cyano, nitro, hydroxy, alkoxy C1 to 6, trifluoromethyl and trifluoromethoxy;
 R², R¹⁴, R¹⁵, R¹⁶ and R⁹ independently represent hydrogen or alkyl C1 to 6;
 in addition, when Y represents NR⁹, —NR⁹R¹³ may together represent a pyrrolidine or piperidine ring; and
 R⁷ and R⁸ independently represent hydrogen, alkyl C1 to 6 or phenyl optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, cyano, nitro, hydroxy, alkoxy C1 to 6 and trifluoromethyl;
 provided that:
 (a) when neither X nor Y represents a bond then n represents an integer 2 to 4;
 (b) when R¹³ represents cyano then Y represents a bond and either X also represents a bond or X does not represent a bond and n represents an integer 1 to 4;
 or a pharmaceutically acceptable salt thereof.



wherein

R^1 represents hydrogen, alkyl C1 to 6, alkoxy C1 to 6, alkylthio C1 to 6 or halogen;
 R^3 represents phenyl or a six membered heterocyclic aromatic ring containing 1 to 3 nitrogen atoms, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1

to 6, alkoxy C1 to 6, halogen, hydroxy, alkylthio C1 to 6, cyano, trifluoromethyl, nitro, hydroxymethyl or a group —NR⁵R⁶,


or R³ represents a five membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S optionally substituted by alkyl C1 to 6 or halogen,

5 or R³ represents hydrogen or alkyl C1 to 8; and


R², R⁴, R⁵ and R⁶ independently represent hydrogen or alkyl C1 to 6;

or a pharmaceutically acceptable salt thereof.

Preferred COX-2 inhibitors for use in the combinations of the invention include those disclosed in WO 96/41626, in particular the compound known as Celecoxib (Searle - compound 2 below). Other preferred COX-2 inhibitors for use in the combinations of the invention include those disclosed in Drugs of the Future, 1997, 22, 711 - 714 which document is incorporated herein by reference, namely (1) Meloxicam, (3) L-745337 (Merck), (4) MK-966 (Merck), (5) L-768277 (Merck), GR-253035 (Glaxo-Wellcome), JTE-522 (Japan Tobacco), (8) RS-57067-000 (Roche), (9) SC-58125 (Searle), (10) SC-078 (Searle), (11) PD-138387 (Warner-Lambert), NS-398 (Taisho), flosulide and (12) PD-164387 (Warner-Lambert).



More preferably the COX-2 inhibitor is Celecoxib or MK-966:



The combination of an iNOS inhibitor and a COX-2 inhibitor would be used to treat other inflammation associated disorders, such as an analgesic for pain and headaches or as an antipyretic for the treatment of fever. The combination would be used to treat arthritis and other skeletal muscular conditions, for example rheumatoid arthritis, osteoarthritis, spondyloerthritis, gouty arthritis, juvenile arthritis and systemic lupus erythematosus and tendinitis. The combinations would also be used to treat asthma, chronic obstructive pulmonary disease, bronchitis, adult respiratory distress syndrome and other conditions of pulmonary inflammation such as cystic fibrosis and those associated with viral infection. The combination would also be used to treat inflammatory conditions of the skin such as psoriasis, eczema, dermatitis and burns. The combination would also be used to treat inflammatory diseases of the gastrointestinal tract such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), gastritis and peptic ulceration and also irritable bowel syndrome. In addition the combination would also be useful in the treatment of cancer, including colorectal cancer and breast cancer. The combination would also be useful in the treatment of inflammatory conditions of the vascular system such as atherosclerosis, periarthritis nodosa and migraine.

The invention therefore provides a combination as described herein for use in therapy, that is for both treatment and prophylaxis of a disease.

5 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

10

By the term "combination" is meant any pharmaceutical composition in which the iNOS inhibitor and the COX-2 inhibitor are administered in a single dosage unit, for example a single tablet or capsule containing a fixed ratio of the two active ingredients, as well as combination therapy in which the iNOS inhibitor and the COX-2 inhibitor are administered 15 in separate dosages, that is to say, administration of each agent simultaneously or sequentially.

20 In a further aspect the invention relates to a kit comprising one or more unit doses of an iNOS inhibitor or a pharmaceutically acceptable salt thereof and one or more unit doses of a COX-2 inhibitor or a pharmaceutically acceptable salt thereof. Such kits can, for example, be in the form of blister packs containing each medicament in separate unit doses.

25 For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a daily dosage of the solid form of between 1 mg and 2000 mg per day.

30 The combinations of the invention may be used on their own, or preferably as a pharmaceutical composition in which the compounds or derivatives are in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. For example in a form appropriate

for enteral or parenteral administration. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of the compound or derivative. Examples of suitable adjuvants, diluents and carriers are well known to a person skilled in the art and include microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and/or gelatin.

According to a further aspect of the invention there is provided a pharmaceutical composition comprising a combination of an iNOS inhibitor and a COX-2 inhibitor as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

According to a further aspect of the invention there is thus provided the use of a combination of an iNOS inhibitor and a COX-2 inhibitor as hereinbefore defined or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment or prophylaxis of a reversible obstructive airways disease.

In a further aspect the invention provides a method of treatment or prophylaxis of inflammatory conditions which comprises administering to a host suffering from or susceptible to such conditions a combination of an iNOS inhibitor and a COX-2 inhibitor as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention is illustrated by the experimental data given below.

25

**Assessment of anti-inflammatory activity in the rat carrageenan paw oedema
(C. A. Winter et al., Proc. Soc. Exp. Biol. Med. 1962, 111, 544)**

Inflammation was induced in the right hind paw of 180-250g Charles River CD male rats by the injection of 0.1ml of 1% carrageenan (Marine Colloids) in saline into the plantar region of the foot. Paw volume was measured by plethysmography before carrageenan

injection and at 2, 4 and 6 hours after the intra-plantar injection. Paw oedema for each rat was calculated as the increase in paw volume over the initial paw volume measured prior to carrageenan injection. Inhibition of oedema for the treatments was calculated as a percentage inhibition of the mean absolute increase in foot volume in treated animals

5 compared to control animals.

The rats were housed on sawdust and fasted overnight prior to the day of the experiment (water available *ad libitum*). The animals had free access to 5% glucose in water throughout the course of the experiment, and were re-fed after the 4 hour measurement.

10 The ankle joint of each right hind paw was marked the day prior to the experiment to indicate the level to which the paw volume would be measured in the experiment.

Carrageenan was prepared the day prior to the experiment by suspending carrageenan in saline (1% w/v) and stirring vigorously on a magnetic stirrer for at least one hour. The

15 suspension was stored at 4°C until required and allowed to reach room temperature prior to use. The drugs were administered to groups of 6 rats 30 mins prior to carrageenan injection either orally (5ml/kg) or subcutaneously (2ml/kg). The COX-2 inhibitors were prepared for oral dosing in suspensions in 0.25% carboxymethylcellulose containing 1.5% Tween 80 (sonicated until dispersed). The iNOS inhibitor was dosed subcutaneously in 6% glucose

20 in distilled water (dissolved by sonication for 5 min).

An iNOS inhibitor or COX-2 inhibitor alone only produced a partial block of the inflammatory response, while a combination of the two produced a higher level of inhibition as shown in the Table below which shows anti-inflammatory activity 4 or 6 hours after administration of the carrageenan:


25

	Experiment 1 % inhibition	Experiment 2 % inhibition
1. iNOS (n = 6)	35	11
2. COX-2 (n = 6)	35	32
1 and 2 (n = 6)	74	63

1. iNOS = 1-(6-cyano-3-pyridylcarbonyl)-5',8'-difluorospiro[piperidine-4,2'(1'H)-quinazoline]-4'-amine hydrochloride (30 μ mol/kg).
1. COX-2 = Celecoxib (3mg/kg).

CLAIMS

1. A pharmaceutical combination comprising a COX-2 inhibitor or a pharmaceutically acceptable salt thereof and a compound of formula (I):



wherein:-

R¹ and R¹⁹ independently represent hydrogen, alkyl C1 to 6, alkoxy C1 to 6, alkylthio C1 to 6, halogen, hydroxyl or amino;

(i) R³ represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1 to 6, alkoxy C1 to 6, halogen, hydroxyl, alkylthio C1 to 6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group —(CH₂)_c·NHCO₂R¹⁰, a group —(CH₂)_c·NR⁵R⁶, or a group —CO₂R¹¹; and R⁴ represents hydrogen or alkyl C1 to 6; or

(ii) R³ represents hydrogen or alkyl C1 to 8, which alkyl group may be optionally substituted by amino or a group —NHCO₂R¹⁰; and R⁴ represents hydrogen or alkyl C1 to 6; or

(iii) R³ and R⁴ taken together represent a group (CH₂)_a·Z·(CH₂)_b;

c represents zero, 1 or 2;

a and b independently represent an integer 1 to 3;

Z represents CH₂, NH, a group >N(CH₂)_nYR¹³, a group >NCOX(CH₂)_nYR¹³, a group >NCSX(CH₂)_nYR¹³, or a group >NCNHN(CH₂)_nYR¹³;

X represents O, S or a bond;

Y represents O, S, SO, SO₂, NR⁹ or a bond;

n represents zero or an integer from 1 to 6;

5 (a) R¹³ represents alkyl C1 to 6, cyano, quinolyl, phenyl, naphthyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, a benzene ring fused with a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S or alkyl C1 to 6 substituted by one or more halogen atoms or

10 (b) R¹³ may be as defined in (a) except that when it contains one or more aromatic rings, said rings may be optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl, trifluoromethoxy, methanesulphonyl, sulphamoyl, —NR¹⁴R¹⁵, —COOR¹⁶ or —CONR⁷R⁸; or

15 (c) R¹³ may represent a phenyl ring, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S substituted by:

benzyloxy or optionally substituted phenyl or an optionally substituted 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S;

wherein the optional substituents are alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl and trifluoromethoxy; or

20 (d) R¹³ may be as defined in (a), (b) or (c) except that when it contains a heterocyclic aromatic ring containing at least one nitrogen atom, said ring may be optionally substituted by one or more oxo groups adjacent to the nitrogen, the ring being attached to the remainder of the molecule through one of the nitrogen atoms or otherwise;

25 R², R⁵, R⁶, R¹¹, R⁹, R¹⁴, R¹⁵ and R¹⁶ independently represent hydrogen or alkyl C1 to 6; in addition, when Y represents NR⁹, —NR⁹R¹³ may together represent a pyrrolidine or piperidine ring;

R^{10} represents alkyl C1 to 6; and

R^7 and R^8 independently represent hydrogen, alkyl C1 to 6 or phenyl optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, cyano, nitro, hydroxyl, alkoxy C1 to 6, trifluoromethyl and trifluoromethoxy;

5 or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.

2. A combination as claimed in Claim 1, wherein in formula (I) R^3 and R^4 taken together represent a group $(CH_2)_a \cdot Z \cdot (CH_2)_b$, in which Z represents a group $>NCO(CH_2)_nR^{13}$, a group $>NCS(CH_2)_nR^{13}$, or a group $>NCNH(CH_2)_nR^{13}$ and R^{13} represents optionally substituted phenyl, furyl, thienyl, thiazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyridyl or pyrazinyl.
- 10
3. A combination as claimed in claim 2, wherein in formula (I) R^{13} represents substituted phenyl or substituted pyridyl, wherein the substituent is in the *para* position.
- 15
4. A combination as claimed in claim 2 or claim 3, wherein in formula (I) n represents 0.
5. A combination as claimed in any preceding claim, wherein R^3 and R^4 taken together represent a group $(CH_2)_a \cdot Z \cdot (CH_2)_b$, in which a and b each represents 2.
- 20
6. A combination as claimed in claim 1, wherein in formula (I) R^4 represents hydrogen and R^3 represents ethyl, isopropyl, cyclopropyl, cyclobutyl, furyl, thienyl or substituted phenyl wherein the substituent is fluoro or hydroxyl.
- 25
7. A combination as claimed in claim 1, wherein in formula (I) R^3 and R^4 taken together represent a group $(CH_2)_a \cdot Z \cdot (CH_2)_b$, in which Z represents a group $>NCO_2(CH_2)_nYR^{13}$ or $>NCSO(CH_2)_nYR^{13}$.

8. A combination as claimed in claim 7, in which n represents 0, Y represents a bond and R¹³ represents alkyl C1 to 6 or chloroalkyl C3 to 6.
9. A combination as claimed in claim 7, in which n represents 2, Y represents oxygen and R¹³ represents optionally substituted phenyl.
10. A combination as claimed in any preceding claim, wherein in formula (I) R¹ and R¹⁹ independently represent hydrogen or halogen.
11. A combination as claimed in claim 10, wherein at least one of R¹ and R¹⁹ represents fluoro or chloro.
12. A combination as claimed in claim 11, wherein R¹ represents 5-fluoro or 5-chloro.
13. A combination as claimed in claim 12, wherein R¹ represents 5-fluoro and R¹⁹ represents 8-fluoro.
14. A combination as claimed in any preceding claim, wherein in formula (I) R² represents hydrogen.

20

15. A combination as claimed in claim 1, wherein the compound of formula (I) is:-
1,2-dihydro-2-phenyl-4-quinazolinamine;
1,2-dihydro-4-quinazolinamine;
1,2-dihydro-2-methyl-4-quinazolinamine;
2-ethyl-1,2-dihydro-4-quinazolinamine;
2-cyclopropyl-1,2-dihydro-4-quinazolinamine;
2-cyclobutyl-1,2-dihydro-4-quinazolinamine;

2-cyclopentyl-1,2-dihydro-4-quinazolinamine;
1,2-dihydro-2,2-dimethyl-4-quinazolinamine;
2-ethyl-1,2-dihydro-2-methyl-4-quinazolinamine;
1,2-dihydro-2-methyl-2-phenyl-4-quinazolinamine;
5 2-(2-furyl)-1,2-dihydro-4-quinazolinamine;
1,2-dihydro-2-(2-thienyl)-4-quinazolinamine;
1,2-dihydro-2-(4-pyridyl)-4-quinazolinamine;
1,2-dihydro-2-(1H-imidazol-2-yl)-4-quinazolinamine;
10 1,2-dihydro-2-(2-thiazolyl)-4-quinazolinamine;
2-(4-cyanophenyl)-1,2-dihydro-4-quinazolinamine;
2-(4-dimethylaminophenyl)-1,2-dihydro-4-quinazolinamine;
1,2-dihydro-2-(4-nitrophenyl)-4-quinazolinamine;
2-(9-anthracenyl)-1,2-dihydro-4-quinazolinamine;
2-(4-amino-1,2-dihydroquinazolin-2-yl)benzenemethanol;
15 1,2-dihydro-2-(2-nitrophenyl)-4-quinazolinamine;
1,2-dihydro-2-(5-nitro-2-thienyl)-4-quinazolinamine;
ethyl 2-(4-amino-1,2-dihydroquinazolin-2-yl)-1H-pyrrole-1-carboxylate;
1,2-dihydro-2-(trimethylsilylethynyl)-4-quinazolinamine;
spiro[cyclopentane-1,2'(1' H)-quinazoline]-4'-amine;
20 spiro[cyclohexane-1,2'(1' H)-quinazoline]-4'-amine;
5-chloro-2-(2-furyl)-1,2-dihydro-4-quinazolinamine;
5-chloro-1,2-dihydro-2-(2-thienyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-phenyl-4-quinazolinamine;
5-fluoro-2-(2-furyl)-1,2-dihydro-4-quinazolinamine;
25 5-fluoro-1,2-dihydro-2-(2-hydroxyphenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(3-hydroxyphenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(4-hydroxyphenyl)-4-quinazolinamine;
ethyl 3-(4-Amino-5-fluoro-1,2-dihydroquinazolin-2-yl)-1H-pyrrole-1-carboxylate;
5-fluoro-1,2-dihydro-2-(2-thienyl)-4-quinazolinamine;
30 5-fluoro-1,2-dihydro-2-(2-thiazolyl)-4-quinazolinamine;

5-fluoro-2-(4-fluorophenyl)-1,2-dihydro-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(4-methoxyphenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(4-(methylthio)phenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(2-(trifluoromethyl)phenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(4-(trifluoromethyl)phenyl)-4-quinazolinamine;
5-fluoro-1,2-dihydro-2-(1-methylethyl)-4-quinazolinamine;
2-cyclobutyl-5-fluoro-1,2-dihydro-4-quinazolinamine;
5-fluoro-2-(2-furyl)-1,2-dihydro-2-methyl-4-quinazolinamine;
2-(2-furyl)-5-(methylthio)-1,2-dihydro-4-quinazolinamine;
1,2-dihydro-1-methyl-2-phenyl-4-quinazolinamine;
2-cyclopropyl-1,2-dihydro-1-methyl-4-quinazolinamine;
4-amino-1,2-dihydro-2-quinazolinepropanamine;
4-amino-1,2-dihydro-2-quinazolineethanamine;
2-(2-(2-azidoethyl)phenyl)-1,2-dihydro-4-quinazolinamine;
15 ethyl *N*-(4-amino-1,2-dihydroquinazolin-2-ylpropyl)carbamate;
ethyl *N*-(4-amino-1,2-dihydroquinazolin-2-ylethyl)carbamate;
ethyl *N*-(4-amino-1,2-dihydroquinazolin-2-ylmethyl)carbamate;
1-(2-thiazolylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-methoxybenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
20 1-(4-cyanobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-nitrobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(2-furylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-ethylbenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-chlorobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
25 1-(2-nitrobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(3-nitrobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(2-methylbenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(3-methylbenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(2-thienylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;

1-((4-hydroxybenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3-hydroxybenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-(phenylmethoxy)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-(4,4-dimethyloxazolin-2-yl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-
5 amine;
1-(2-pyridylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-pyridylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3-pyridazinylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3,5-dimethylbenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
10 1-(3-fluoro-4-methylbenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3,5-difluorobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-(1,2,3-thiadiazol-4-yl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-bromobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-iodobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
15 1-(4-(trifluoromethyl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-(methanesulphonyl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-fluorobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(5-bromo-2-furylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-([1,1'-biphenyl]-4-ylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
20 1-(5-chloro-2-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3-pyridylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-(aminosulphonyl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(4-methylbenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(3-amino-4-chlorobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
25 1-((2-(trifluoromethyl)phenyl)acetyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
methyl 4-(4'-aminospiro[piperidine-4,2'(1' H)-quinazoline]-1-ylcarbonyl)benzoate;
1-(4-(1H-pyrrol-1-yl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
4'-aminospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxamide;

1-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(2-thiazolyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-nitrophenylsulphonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-methoxyphenylsulphonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5 1-(methanesulphonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(1-oxobutyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-chloro-1-(4-cyanobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-chloro-1-(2-thienylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-chloro-1-(2-furylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
10 1-(4-cyanobenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-fluoro-1-(2-fluorobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-chlorobenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-bromobenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-fluoro-1-(4-iodobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
15 5'-fluoro-1-(4-nitrobenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-ethylbenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-fluoro-1-(4-propylbenzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-butylbenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-ethynylbenzoyl)-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
20 5'-fluoro-1-((4-aminosulphonyl)benzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-fluoro-1-((4-methanesulphonyl)benzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5'-fluoro-1-(4-(trifluoromethoxy)benzoyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
25 methyl 4-(4'-Amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-ylcarbonyl)-benzoate;
4-(4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-ylcarbonyl)-N-(2-hydroxy-phenyl)benzamide;

4-(4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-ylcarbonyl)-N-(4-methoxyphenyl)benzamide;

5'-fluoro-1-(4-(2-thiazolyl)benzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(3,4-dichlorobenzoyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5 1-(4-chloro-3-iodobenzoyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(4-cyano-3-methylbenzoyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(4-cyano-3-fluorobenzoyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(2-furylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(2-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

10 5'-fluoro-1-(3-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(4-bromo-2-thienylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(5-bromo-3-thienylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(5-chloro-2-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(5-bromo-2-thienylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

15 5'-fluoro-1-(5-methyl-2-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(5-ethyl-2-thienylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(1H-pyrrol-2-ylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(1-methyl-1H-pyrrol-2-ylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

20 5'-fluoro-1-(3-isoxazolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(5-isoxazolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(2-thiazolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(5-thiazolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(2-(3-bromo-2-thienyl)-5-thiazolylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quin-
25 azoline]-4'-amine;

5'-fluoro-1-(4-isothiazolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(1,2,3-thiadiazol-4-ylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(4-pyridylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5'-fluoro-1-(3-pyridylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(6-chloro-3-pyridylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(6-cyano-3-pyridylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5 5'-fluoro-1-(2-pyrazinylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5'-fluoro-1-(5-methyl-2-pyrazinylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5'-fluoro-1-(2-naphthylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5'-fluoro-1-(2-benzo[b]thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
10 5'-fluoro-1-(6-quinolylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(1,3-benzodioxol-5-ylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(5-benzofuroxanylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-(1,3-dihydro-1,3-dioxo-2H-isoindol-5-ylcarbonyl)-5'-fluorospiro[piperidine-4,2'(1' H)-
15 quinazoline]-4'-amine;
O-ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carbothioate;
5'-fluoro-1-(2-thienyl)iminomethylspiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-((4-cyanophenyl)thioxomethyl)-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
20 5'-fluoro-1-(trifluoroacetyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
5'-fluoro-1-(4-phenoxybutanoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
3-(methanesulphonyl)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-
carboxylate;
5'-fluoro-1'-methyl-1-(2-thienylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-
25 amine;
5'-fluoro-1'-methyl-1-(4-cyanobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;
1-((4-aminosulphonyl)benzoyl)-5'-fluoro-1'-methyl-spiro[piperidine-4,2'(1' H)-quin-
azoline]-4'-amine;
1-(4-cyanobenzoyl)-5',8'-difluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

1-(4-chlorobenzoyl)-5',8'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5',8'-difluoro-1-(2-thienylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5',8'-difluoro-1-(2-pyrazinylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(6-chloro-3-pyridylcarbonyl)-5',8'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-
5 amine;
1-(6-cyano-3-pyridylcarbonyl)-5',8'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-
amine;
1-(4-cyanobenzoyl)-5',7'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
5',7'-difluoro-1-(2-thienylcarbonyl)spiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
10 1-(4-cyanobenzoyl)-5'-methoxyspiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-bromobenzoyl)-5'-hydroxyspiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
1-(4-cyanobenzoyl)-5'-hydroxyspiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
ethyl 4'-aminospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
1-acetylspiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
15 methyl 4'-aminospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
1-methylethyl 4'-aminospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
1-benzoylspiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
ethyl 4'-amino-5'-chlorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
20 1-benzoyl-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-4'-amine;
ethyl 4'-amino-5'-hydroxyspiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-amino-5'-methoxyspiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-amino-5',8'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-amino-5',7'-difluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
25 ethyl 4'-amino-8'-chloro-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-amino-5'-fluoro-1'-methylspiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-aminospiro[piperidine-3,2'(¹ H)-quinazoline]-1-carboxylate;
ethyl 4'-aminospiro[pyrrolidine-3,2'(¹ H)-quinazoline]-1-carboxylate;

propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
methyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
2-methylpropyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
cyclopentyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
5 2-methoxyethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
S-ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carbothioate;
2-phenoxyethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
1-methylethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
butyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
10 pentyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
hexyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
cyclobutyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
prop-2-yn-1-yl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
but-3-yn-1-yl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
15 pent-4-yn-1-yl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
hex-5-yn-1-yl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
2,2,2-trifluoroethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carb-
oxylate;
4,4,4-trifluorobutyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carb-
20 oxylate;
3-chloropropyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
4-chlorobutyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
5-chloropentyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
6-chlorohexyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
25 2-cyanoethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carboxylate;
2-(methylthio)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carb-
oxylate;
3-(methylthio)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(¹ H)-quinazoline]-1-carb-

oxylate;

2-phenylethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

3-phenylpropyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

4-phenylbutyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

5 2-(2-pyridyl)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

2-(3-pyridyl)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

3-(2-pyridyl)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
10 oxylate;

2-(2-pyridylthio)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

2-(phenylthio)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

15 2-(phenylamino)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

2-(*N*-ethyl-*N*-phenylamino)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quin-
azoline]-1-carboxylate;

2-(4-chlorophenoxy)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-
20 1-carboxylate;

2-benzofuranyl methyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

3-phenoxypropyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

2-(2-thienyl)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
25 oxylate;

3-(2-thienyl)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

4-(2-thienyl)butyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carb-
oxylate;

2-(phenylmethoxy)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

5 3-(2-oxo-1(2H)-pyridyl)propyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

2-(phenylmethoxy)phenyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

5-bromo-2-methoxyphenylmethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

10 2-(4-methyl-5-thiazolyl)ethyl 4'-amino-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

phenyl 4'-aminospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

4-chlorobutyl 4'-amino-5',8'-difluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

15 4-chlorobutyl 4'-amino-5'-fluoro-1'-methylspiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxylate;

4'-amino-5'-fluoro-1-(1H-imidazol-1-ylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline];

5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-4'-amine;

20 spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;

1-(phenylmethyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;

1-(phenylmethyl)spiro[piperidine-3,2'(1' H)-quinazoline]- 4'-amine;

1-(phenylmethyl)spiro[pyrrolidine-3,2'-[1' H]-quinazoline]- 4'-amine;

5'-fluoro-1-(phenylmethyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;

25 5'-fluoro-1-(1-pyrrolidinylcarbonyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;

4'-amino-N-ethyl-5'-fluorospiro[piperidine-4,2'(1' H)-quinazoline]-1-carboxamide;

ethyl 4'-amino-5'-fluorospiro[azetidine-3,2'(1' H)-quinazoline]-1-carboxylate;

phenylmethyl 4'-amino-5'-fluorospiro[azetidine-3,2'(1' H)-quinazoline]-1-carboxylate;

5'-fluorospiro[azetidine-3,2'(1' H)-quinazoline]-4'-amine;

5'-fluoro-1-(2-thienylcarbonyl)spiro[azetidine-3,2'(1' H)-quinazoline]-4'-amine;
1-(3,5-dimethylisoxazol-4-yl)sulphonyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;
2-ethynyl-1,2-dihydro-4-quinazolinamine;
2-(2-(2-aminoethyl)phenyl)-1,2-dihydro-4-quinazolinamine;
5 1-(4-aminobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine;
1-(3-aminobenzoyl)spiro[piperidine-4,2'(1' H)-quinazoline]- 4'-amine; or
4-(4'-aminospiro[piperidine-4,2'(1' H)-quinazoline]-1-ylcarbonyl)benzoic acid;
or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.

10 16. A combination as claimed in any one of claims 1 to 15, comprising as a COX-2 inhibitor, at least one of Celecoxib, Meloxicam, L-745337, MK-966, L-768277, GR-253035, JTE-522, RS-57067-000, SC-58125, SC-078, PD-138387, NS-398, Flosulide and PD-164387, or pharmaceutically acceptable salts, enantiomers or tautomers thereof.

15 17. A combination as claimed in any one of claims 1 to 15, wherein the COX-2 inhibitor is Celecoxib or MK-966, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.

18. A combination according to any one of claims 1 to 17 for use in therapy.

20 19. Use of the combination as claimed in any one of claims 1 to 17 in the manufacture of a medicament for the treatment or prophylaxis of inflammatory disease.

25 20. A method of treatment of an inflammatory disease in a person suffering from or susceptible to such a disease, which method comprises administering to the person a therapeutically effective amount of a combination according to any one of claims 1 to 17.

21. A pharmaceutical composition comprising a combination according to any one of claims 1 to 17 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01144

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/505, A61K 31/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9714686 A1 (ASTRA PHARMACEUTICALS LIMITED), 24 April 1997 (24.04.97) --	1-21
P,A	STN International, File MEDLINE, Medline accession no. 1999000472, Hamilton L C et al: Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib"; & British Journal of Pharmacology, (1998 Sep) 125 (2) 335-40 -----	1-21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
4 October 1999	22-10-1999
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer Solveig Gustavsson/EÖ Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE 99/01144**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 20
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/01144

Claim 20 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/08/99

International application No.

PCT/SE 99/01144

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9714686 A1	24/04/97	AU 704133 B	15/04/99
		AU 7224396 A	07/05/97
		BR 9610988 A	06/04/99
		CZ 9801193 A	16/09/98
		EP 0858451 A	19/08/98
		GB 9521231 D	00/00/00
		HU 9900028 A	28/04/99
		NO 981710 A	03/06/98
		PL 326353 A	14/09/98
		US 5883102 A	16/03/99
		AU 697282 B	01/10/98
		AU 7321796 A	22/05/97
		EP 0854996 A	29/07/98
		GB 9602668 D	00/00/00
		GB 9614386 D	00/00/00